Top Clinical Trials companies in Japan by Debt to Equity Ratio
Japan
# |
Name |
Debt to Equity Ratio |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
1.56
|
March 31, 2024 | USD 18.45 | 0.04% |
|
Japan |
|
| 2 |
1.11
|
Dec. 31, 2023 | USD 6.49 | 2.23% |
|
Japan |
|
| 3 |
0.89
|
March 31, 2024 | USD 5.69 | -0.47% |
|
Japan |
|
| 4 |
0.81
|
June 30, 2024 | USD 8.33 | -0.82% |
|
Japan |
|
| 5 |
0.77
|
March 31, 2024 | USD 11.72 | -4.48% |
|
Japan |
|
| 6 |
0.67
|
March 31, 2024 | USD 27.32 | -0.70% |
|
Japan |
|
| 7 |
0.64
|
Sept. 30, 2024 | USD 9.11 | -4.98% |
|
Japan |
|
| 8 |
0.63
|
March 31, 2024 | USD 9.47 | 0.08% |
|
Japan |
|
| 9 |
0.60
|
March 31, 2024 | USD 10.06 | -1.25% |
|
Japan |
|
| 10 |
0.58
|
Dec. 31, 2023 | USD 12.89 | -3.06% |
|
Japan |
|
| 11 |
0.41
|
March 31, 2024 | USD 3.51 | 6.45% |
|
Japan |
|
| 12 |
0.40
|
March 31, 2024 | USD 2.10 | -1.79% |
|
Japan |
|
| 13 |
0.35
|
March 31, 2024 | USD 2.29 | -0.24% |
|
Japan |
|
| 14 |
0.32
|
March 31, 2024 | USD 0.92 | -1.38% |
|
Japan |
|
| 15 |
0.30
|
March 31, 2024 | USD 0.17 | 0.04% |
|
Japan |
|
| 16 |
0.24
|
Jan. 31, 2024 | USD 6.33 | 18.59% |
|
Japan |
|
| 17 |
0.21
|
Dec. 31, 2023 | USD 3.76 | 2.75% |
|
Japan |
|
| 18 |
0.16
|
March 31, 2024 | USD 9.07 | -0.68% |
|
Japan |
|
| 19 |
0.11
|
March 31, 2024 | USD 9.54 | -0.95% |
|
Japan |
|
| 20 |
0.11
|
Dec. 31, 2023 | USD 22.49 | -0.83% |
|
Japan |
|
| 21 |
0.06
|
Dec. 31, 2023 | USD 2.63 | -0.70% |
|
Japan |
|
| 22 |
0.05
|
Dec. 31, 2023 | USD 1.92 | 0.39% |
|
Japan |
|
| 23 |
0.03
|
Dec. 31, 2023 | USD 0.24 | -2.59% |
|
Japan |
|
| 24 |
0.03
|
March 31, 2024 | USD 15.30 | -0.34% |
|
Japan |
|
| 25 |
0.01
|
March 31, 2024 | USD 14.33 | -1.63% |
|
Japan |
|
| 26 |
0.01
|
Dec. 31, 2023 | USD 45.71 | 2.52% |
|
Japan |
|
| 27 |
0.01
|
March 31, 2024 | USD 24.50 | -0.22% |
|
Japan |
|
| 28 |
0.00
|
March 31, 2024 | USD 11.63 | 0.67% |
|
Japan |
|
| 29 |
0.00
|
June 30, 2024 | USD 1.01 | 1.37% |
|
Japan |
|
| 30 |
0.00
|
Dec. 31, 2023 | USD 13.98 | -5.45% |
|
Japan |
|
| 31 |
0.00
|
March 31, 2024 | USD 1.31 | -20.36% |
|
Japan |
Frequently Asked Questions
-
Which Clinical Trials company in Japan has the highest Debt to Equity Ratio ?
The Clinical Trials company in Japan with the highest Debt to Equity Ratio is I'rom Group Co., Ltd. (Tokyo Stock Exchange: 2372.T) at 1.56.
-
Which Clinical Trials company in Japan has the lowest Debt to Equity Ratio ?
The Clinical Trials company in Japan with the lowest Debt to Equity Ratio is ReproCELL Incorporated (Tokyo Stock Exchange: 4978.T) at 0.00.
-
What are the top 10 Clinical Trials companies in Japan by Debt to Equity Ratio ?
The top 10 Clinical Trials companies in Japan by Debt to Equity Ratio are I'rom Group Co., Ltd., Nxera Pharma Co., Ltd., Cytori Cell Research Institute, Inc., Macromill, Inc., Shin Nippon Biomedical Laboratories, Ltd., Takeda Pharmaceutical Company Limited, Fuji Pharma Co., Ltd., Astellas Pharma Inc., Qol Holdings Co., Ltd. and PeptiDream Inc..
-
What are the bottom 10 Clinical Trials companies in Japan by Debt to Equity Ratio ?
The bottom 10 Clinical Trials companies in Japan by Debt to Equity Ratio are ReproCELL Incorporated, Kyowa Kirin Co., Ltd., Soiken Holdings Inc., WDB Holdings Co., Ltd., Kissei Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., FALCO HOLDINGS Co., Ltd., Solasia Pharma K.K. and Carna Biosciences, Inc..
